Related references
Note: Only part of the references are listed.Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019
Fiona Y- Pham et al.
INTERNATIONAL JOURNAL OF CANCER (2022)
Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks
Arnaud Bayle et al.
EUROPEAN JOURNAL OF CANCER (2021)
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
Amanda Katherina Herbrand et al.
JAMA NETWORK OPEN (2021)
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Emmanuelle Jacquet et al.
EUROPEAN JOURNAL OF CANCER (2021)
Right to Try, expanded access use, Project Facilitate, and clinical trial reform
N. K. Reddy et al.
ANNALS OF ONCOLOGY (2021)
Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018
Kerstin N. Vokinger et al.
HEALTH POLICY (2020)
Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
Carin A. Uyl-de Groot et al.
CANCERS (2020)
Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe
Alison Cave et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Patient Access to Medicines for Rare Diseases in European Countries
Andreja Deticek et al.
VALUE IN HEALTH (2018)
Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden
Alessandra Ferrario
VALUE IN HEALTH (2018)
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
L. Kandolf Sekulovic et al.
EUROPEAN JOURNAL OF CANCER (2018)
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Lixian Zhong et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Industry corner: perspectives and controversies - The challenges of patient access to new medicines
C. -N. Gann et al.
ANNALS OF ONCOLOGY (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
Pawel Kawalec et al.
FRONTIERS IN PHARMACOLOGY (2017)
ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Early market access of cancer drugs in the EU
J. Martinalbo et al.
ANNALS OF ONCOLOGY (2016)
ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe
N. Cherny et al.
ANNALS OF ONCOLOGY (2016)
An overview of Compassionate Use Programs in the European Union member states
Gayathri Balasubramanian et al.
INTRACTABLE & RARE DISEASES RESEARCH (2016)
Systematic overview of cost-effectiveness thresholds in ten countries across four continents
Ruth Schwarzer et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2015)
Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions
Elena Nicod et al.
HEALTH POLICY (2012)
Disparity in the time to patient access to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM)
Stefania Gori et al.
TUMORI (2011)
Share Paper
